litlas
Log inCreate account

Michael Grundman

Active 1986–2026

73
Papers
23,668
Citations
58
h-index
70
i10-index

Citations

Citations per year for Michael Grundman1987: 2 citations1988: 5 citations1989: 2 citations1990: 4 citations1991: 5 citations1992: 7 citations1993: 7 citations1994: 4 citations1995: 5 citations1996: 6 citations1997: 12 citations1998: 47 citations1999: 55 citations2000: 116 citations2001: 159 citations2002: 171 citations2003: 153 citations2004: 206 citations2005: 234 citations2006: 276 citations2007: 252 citations2008: 274 citations2009: 218 citations2010: 325 citations2011: 342 citations2012: 310 citations2013: 331 citations2014: 364 citations2015: 299 citations2016: 303 citations2017: 276 citations2018: 292 citations2019: 709 citations2020: 721 citations2021: 707 citations2022: 622 citations2023: 508 citations2024: 694 citations2025: 399 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,557 citing papers, 31.5% of this breakdownUnited Kingdom: 993 citing papers, 8.8% of this breakdownChina: 633 citing papers, 5.6% of this breakdownGermany: 543 citing papers, 4.8% of this breakdownCanada: 490 citing papers, 4.3% of this breakdownItaly: 475 citing papers, 4.2% of this breakdownAustralia: 390 citing papers, 3.5% of this breakdownFrance: 371 citing papers, 3.3% of this breakdownSweden: 356 citing papers, 3.1% of this breakdownSpain: 325 citing papers, 2.9% of this breakdownNetherlands: 315 citing papers, 2.8% of this breakdownJapan: 258 citing papers, 2.3% of this breakdown
0%31.5%Other 22.9%

Institutions

Fields

  • Medicine72.2%
  • Neuroscience11.5%
  • Biochemistry, Genetics and Molecular Biology7.6%
  • Computer Science1.6%
  • Psychology1.5%
  • Nursing1%
  • Other4.6%

Topics

  • Alzheimer's disease research and treatments16.6%
  • Dementia and Cognitive Impairment Research12%
  • Cholinesterase and Neurodegenerative Diseases4.5%
  • Neuroinflammation and Neurodegeneration Mechanisms3.1%
  • Computational Drug Discovery Methods2.6%
  • Parkinson's Disease Mechanisms and Treatments2.6%
  • Other58.6%

Coauthors

All papers

Open in search
  1. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

    Authors: Stephen Salloway, Reisa A. Sperling, Nick C. Fox, Kaj Blennow, William E. Klunk, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Steven H. Ferris, Marcel Reichert, Nzeera Ketter, Bijan Nejadnik, Volkmar Guenzler, Maja Miloslavsky, Daniel Wang, Yuan Lü, Julia Lull, Iulia Cristina Tudor, Enchi Liu, Michael Grundman, Eric Yuen, Ronald S. Black, H. Robert Brashear - New England Journal of Medicine 2014 cited by 1,965

  2. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

    Authors: Reisa A. Sperling, Clifford R. Jack, Sandra E. Black, Matthew P. Frosch, Steven M. Greenberg, Bradley T. Hyman, Philip Scheltens, María C. Carrillo, William Thies, Martin M. Bednar, Ronald S. Black, H. Robert Brashear, Michael Grundman, Eric Siemers, Howard Feldman, Rachel Schindler - Alzheimer s & Dementia 2011 cited by 830

  3. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

    Authors: Reisa A. Sperling, Stephen Salloway, David J. Brooks, Donatella Tampieri, Jerome Barakos, Nick C. Fox, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Ivan Lieberburg, H. Michael Arrighi, Kristen Morris, Yuan Lü, Enchi Liu, Keith M. Gregg, H. Robert Brashear, Gene G. Kinney, Ronald S. Black, Michael Grundman - The Lancet Neurology 2012 cited by 510

  4. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

    Authors: the Synaptic Health Endpoints Working Group, Martí Colom‐Cadena, Tara L. Spires‐Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John Harrison, Lon S. Schneider, Philip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo, Susan M. Catalano - Alzheimer s Research & Therapy 2020 cited by 355

  5. Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs

    Authors: Richard C. Mohs, David S. Knopman, Ronald C. Petersen, Steven H. Ferris, Chris Ernesto, Michael Grundman, Mary Sano, Linas A. Bieliauskas, David Geldmacher, Chris M. Clark, Leon J. Thal - Alzheimer Disease & Associated Disorders 1997 cited by 703

  6. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease

    Authors: Douglas Galasko, David A. Bennett, Mary Sano, Chris Ernesto, Ronald J. Thomas, Michael Grundman, Steven H. Ferris - Alzheimer Disease & Associated Disorders 1997 cited by 1,193

  7. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

    Authors: Joseph Jankovic, Ira Goodman, Beth Safirstein, Tonya Marmon, Dale B. Schenk, Martin Koller, Wagner Zago, Daniel Ness, Sue G. Griffith, Michael Grundman, Jay Soto, Susanne Ostrowitzki, Frank Boess, Meret Martin‐Facklam, Joseph F. Quinn, Stuart Isaacson, Omid Omidvar, Aaron Ellenbogen, Gene G. Kinney - JAMA Neurology 2018 cited by 292

  8. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

    Authors: Tien Dam, Adam L. Boxer, Lawrence I. Golbe, Günter U. Höglinger, Huw R. Morris, Irene Litvan, Anthony E. Lang, Jean‐Christophe Corvol, Ikuko Aiba, Michael Grundman, Lili Yang, Beth Tidemann‐Miller, Joseph Kupferman, Kristine D. Harper, Kubra Kamisoglu, Michael Wald, Danielle Graham, Liz Gedney, John O’Gorman, Samantha Budd Haeberlein, PASSPORT Study Group - Nature Medicine 2021 cited by 138

  9. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

    Authors: Ronald Petersen, Ronald G. Thomas, Michael Grundman, David Bennett, Rachelle S. Doody, Steven H. Ferris, Douglas Galasko, Shelia Jin, Jeffrey Kaye, Allan I. Levey, Eric Pfeiffer, Mary Sano, Christopher H. van Dyck, Leon J. Thal - New England Journal of Medicine 2005 cited by 1,858

  10. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

    Authors: Stephen Salloway, Reisa A. Sperling, S. Gilman, Nick C. Fox, Kaj Blennow, Murray A. Raskind, Marwan N. Sabbagh, Lawrence S. Honig, Rachelle S. Doody, Christopher H. van Dyck, Ruth A. Mulnard, Jerome Barakos, K. M. Gregg, E. Liu, Ivan Lieberburg, Dale Schenk, Ronald S. Black, Michael Grundman - Neurology 2009 cited by 739

  11. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

    Authors: Richard C. Mohs, David S. Knopman, R. Petersen, Steven H. Ferris, Christopher Ernesto, Michael Grundman, Mary Sano, Linas A. Bieliauskas, David Geldmacher, Camilla N. Clark, L. J. Thal - 1997 cited by 493

  12. Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial

    Authors: Florian Lipsmeier, Kirsten I. Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Jens Schjodt‐Eriksen, Wei‐Yi Cheng, Ignacio Fernandez‐Garcia, Juliane Siebourg‐Polster, Liping Jin, Jay Soto, Lynne Verselis, Frank Boess, Martin Koller, Michael Grundman, Andreas U. Monsch, Ronald B. Postuma, Anirvan Ghosh, Thomas Kremer, Christian Czech, Christian Gossens, Michael Lindemann - Movement Disorders 2018 cited by 268

  13. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

    Authors: Mary Sano, Christopher Ernesto, Ronald G. Thomas, Melville R. Klauber, Kimberly Schafer, Michael Grundman, Peter Woodbury, John H. Growdon, Carl W. Cotman, Eric Pfeiffer, Lon S. Schneider, Leon J. Thal - New England Journal of Medicine 1997 cited by 2,383

  14. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

    Authors: Dale B. Schenk, Martin Koller, Daniel Ness, Sue G. Griffith, Michael Grundman, Wagner Zago, Jay Soto, George Atiee, Susanne Ostrowitzki, Gene G. Kinney - Movement Disorders 2016 cited by 248

  15. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

    Authors: Michael Grundman - Archives of Neurology 2004 cited by 971

  16. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease

    Authors: Joseph L. Price, Daniel W. McKeel, Virginia Buckles, Catherine M. Roe, Chengjie Xiong, Michael Grundman, Lawrence A. Hansen, Ronald C. Petersen, Joseph E. Parisi, Dennis W. Dickson, Charles D. Smith, Daron G. Davis, Frederick A. Schmitt, William R. Markesbery, Jeffrey Kaye, Roger Kurlan, Christine Hulette, Brenda F. Kurland, Roger Higdon, Walter A. Kukull, John C. Morris - Neurobiology of Aging 2009 cited by 656

  17. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

    Authors: Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera, Colleen S. Limegrover, Courtney Rehak, Raymond Yurko, Lora Waybright, Gary C. Look, Gilbert M. Rishton, Hank Safferstein, Mary E. Hamby, Claire Williams, Kelsey Sadlek, Hannah M. Edwards, Charles S. Davis, Michael Grundman, Lon S. Schneider, Steven T. DeKosky, Daniel Chelsky, Ian Pike, Christopher M. Henstridge, Kaj Blennow, Henrik Zetterberg, Harry LeVine, Tara L. Spires‐Jones, John R. Cirrito, Susan M. Catalano - Alzheimer s & Dementia 2021 cited by 103

  18. MR Imaging Features of Amyloid-Related Imaging Abnormalities

    Authors: Jerome Barakos, Reisa A. Sperling, Stephen Salloway, Clifford R. Jack, Achim Gass, Jochen B. Fiebach, Donatella Tampieri, D Melançon, Y Miaux, Gregory A. Rippon, Ronald S. Black, Yuan Lü, H. Robert Brashear, H. Michael Arrighi, Kristen Morris, Michael Grundman - American Journal of Neuroradiology 2013 cited by 111

  19. Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases

    Authors: Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, Anthony O. Caggiano, Michael Grundman, Mary E. Hamby - International Journal of Molecular Sciences 2023 cited by 46

  20. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

    Authors: Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad Obadah Nakawah, Gustavo C. Román, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel - Translational Neurodegeneration 2023 cited by 38

  21. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

    Authors: Paul Aisen, Kimberly Schafer, Michael Grundman, Eric Pfeiffer, Mary Sano, Kenneth L. Davis, Martin R. Farlow, Shelia Jin, Ronald G. Thomas, Leon J. Thal - 2003 cited by 968

  22. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

    Authors: Juha O. Rinne, David J. Brooks, Martin N. Rossor, Nick C. Fox, Roger Bullock, William E. Klunk, Chester A. Mathis, Kaj Blennow, Jerome Barakos, Aren Okello, Sofia Rodriguez Martinez de Liano, Enchi Liu, Martin Koller, Keith M. Gregg, Dale Schenk, Ronald S. Black, Michael Grundman - The Lancet Neurology 2010 cited by 695

  23. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

    Authors: Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian, Michael Grundman, Lawrence I. Golbe, Irene Litvan, Lawrence S. Honig, Paul Tuite, Nikolaus R. McFarland, Padraig O’Suilleabhain, Tao Xie, Giridhar Tirucherai, Clifford Bechtold, Yvette Bordelon, David Geldmacher, Murray Grossman, Stuart Isaacson, Theresa Zesiewicz, Tina M. Olsson, Kumar Kandadi Muralidharan, Danielle Graham, John O’Gorman, Samantha Budd Haeberlein, Tien Dam - The Lancet Neurology 2019 cited by 141

  24. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

    Authors: Ronald S. Black, Reisa A. Sperling, Beth Safirstein, Ruth Motter, Allan Pallay, Alice I. Nichols, Michael Grundman - Alzheimer Disease & Associated Disorders 2010 cited by 168